Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

statutory medicines

- PMLiVE

NICE backs Tesaro’s Zejula via the CDF

Recommends the drug for second-line use in ovarian cancer patients

- PMLiVE

Patient outcomes in practice: delivering value that transforms lives

Over the next five years, the NHS needs to drive efficiencies of £22bn. Like all global healthcare systems, it faces the challenge of improving the health of larger and older...

Improving NHS sustainability through service redesign partnerships and effective communications

With year-on-year increases in demand and the imperative to reduce its deficits, the NHS must look beyond merely doing more of the same if it is to become sustainable. Never...

NHS collaborates with VisualDX

CCGs will now have access to diagnostic clinical decision support resource

The NHS and ABPI at 70: inching closer to the triple win

The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...

- PMLiVE

Sir Bruce Keogh is appointed chair of judges for HSJ Awards

Sir Bruce Keogh, the former National Medical Director for NHS England, will chair the judges’ panel for the 37th annual HSJ Awards – the world’s largest healthcare awards programme.

Wilmington Healthcare

- PMLiVE

NHS England pledges to streamline clinical trial setup

The process will also target the procedure for reimbursements in additional treatment costs

- PMLiVE

NHS England’s Simon Stevens – no Trump drug price rhetoric here

Health service supremo will play major role in UK pricing talks

- PMLiVE

Morning brief: Sanofi’s shaky start, pharma begins talks with UK government and more

Sanofi falling behind in Amgen cholesterol battleFirst quarter results from Sanofi show the company has got off to shaky start in 2018, including signs that it its PCKS9 inhibitor cholesterol...

- PMLiVE

NHS chief pledges CAR-T support, but asks for pricing restraint

The plea comes as the EMA reviews two CAR-T therapies

Sanofi reception

NICE rejects Sanofi’s Dupixent for atopic dermatitis at first call

Dupixent is still too expensive despite discount, says the UK’s cost effectiveness body

- PMLiVE

NHS seeks ‘solution creators’ from within pharma

Health service is moving to a 'new era' of industry relations, says NHS England

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links